Study provides insights on optimal treatment of Paget's disease of bone

In a study of patients with Paget's disease of bone—a common skeletal disorder that can lead to bone deformity, fractures, osteoarthritis, and bone pain—long-term intensive bisphosphonate therapy conferred no clinical benefit over giving bisphosphonates only when patients felt bone pain.

Also, long-term bisphosphonate therapy was linked with a non-significant increase in the risk of fractures and serious adverse events.

Although bisphosphonates are effective at suppressing the elevated bone turnover and bone pain that are characteristic of Paget's disease of bone, the study's results suggest that the drugs should be used to control symptoms rather than to suppress bone turnover.

"This is an important study since it shows that clinicians involved in the management of Paget's disease should be treating the patient and not of bone turnover," said Dr. Stuart Ralston, senior author of the Journal of Bone and Mineral Research study. "Bisphosphonates are effective drugs for the treatment of Paget's but our study suggests that striving to normalize biochemical markers may be harmful."

More information: Adrian Tan et al, Long-Term Randomized Trial of Intensive Versus Symptomatic Management in Paget's Disease of Bone: The PRISM-EZ Study, Journal of Bone and Mineral Research (2017). DOI: 10.1002/jbmr.3066

Provided by Wiley
Citation: Study provides insights on optimal treatment of Paget's disease of bone (2017, February 8) retrieved 12 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

IV bisphosphonate Tx linked to drop in bone turnover in DMD


Feedback to editors